Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good day, and thank you for standing by. Welcome to the Myriad ...

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the ...

A new approach reveals genetic interactions that contribute to heart defects. Scientists at the Icahn School of Medicine at ...

In response to a recent reader inquiry regarding the degree of heterosis he could expect in his breeding program, we thought ...

NIMS Medical Genetics department in Hyderabad offers cutting-edge diagnostic and therapeutic services for rare genetic ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that ...

A novel tool for rapidly identifying the genetic 'fingerprints' of cancer cells may enable future surgeons to more accurately remove brain tumors while a patient is in the operating room, new research ...

StockNews.com lowered shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a buy rating to a hold rating in a research ...

Testing is recommended for those with personal and family histories of several types of cancer — including pancreatic and ...

周二，Jefferies分析师将Myriad Genetics的目标股价从此前的$13.00下调至$11.00，同时维持对该公司股票的低配评级。目前该股交易价格为$13.78，根据InvestingPro数据显示，过去六个月股价大幅下跌51%。此次目标价调整是在该公司1月份发布预告以及2025年展望后作出的，其中包括了首席执行官变更的消息。

Environmental and lifestyle factors play a far greater role than genetics in determining the likelihood of dying young, ...